Ovoca Bio plc

LSE OVB.L

Ovoca Bio plc Debt to Equity Ratio for the year ending December 31, 2023

Ovoca Bio plc Debt to Equity Ratio is NA for the year ending December 31, 2023. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

LSE: OVB.L

Ovoca Bio plc

CEO	Mr. Timothy Rand McCutcheon
IPO Date	Jan. 4, 2000
Location	Ireland
Headquarters	17 Pembroke Street Upper
Employees	5
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Ovoca Bio plc, a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. It is developing BP-101, a medicinal treatment for premenopausal women with hypoactive sexual desire disorder, which is in phase II clinical study in Australia and New Zealand, and in phase III clinical trials in Russia. It also engages in mineral exploration, as well as provides support services. The company was formerly known as Ovoca Gold plc and changed its name to Ovoca Bio plc in July 2018. Ovoca Bio plc was incorporated in 1985 and is based in Dublin, Ireland.

Key trends

Past 5 years